GCP
VERV

GSA Capital Partners’s Verve Therapeutics VERV Stock Holding History

GSA Capital Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-38,912
Closed -$437K – 2129
2025
Q2 		$437K Sell
38,912
-179,015
-82% -$1.02M 0.03% 1015
2025
Q1 		$996K Buy
217,927
+78,768
+57% +$528K 0.09% 347
2024
Q4 		$785K Buy
139,159
+103,057
+285% +$581K 0.06% 568
2024
Q3 		$175K Sell
36,102
-167,575
-82% -$973K 0.01% 1436
2024
Q2 		$994K Buy
+203,677
New +$1.28M 0.07% 505
2023
Q4 		– Sell
-56,895
Closed -$754K – 1958
2023
Q3 		$754K Buy
+56,895
New +$916K 0.06% 548
2023
Q2 		– Sell
-54,284
Closed -$783K – 1964
2023
Q1 		$783K Buy
+54,284
New +$1.06M 0.08% 453
2022
Q3 		– Sell
-25,544
Closed -$390K – 1887
2022
Q2 		$390K Buy
+25,544
New +$396K 0.06% 657

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GSA Capital Partners's VERV Position: Q3 2025 in Review

GSA Capital Partners sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 38,912 shares — an estimated $437K sold.

GSA Capital Partners first reported a position in VERV in Q2 2022 and held it in 8 quarters. The position peaked at $996K in Q1 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • GSA Capital Partners reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 38,912 Verve Therapeutics shares in Q3 2025, an estimated $437K.
  • GSA Capital Partners first reported a position in Verve Therapeutics in Q2 2022 and held it in 8 quarters.
  • GSA Capital Partners's Verve Therapeutics position peaked at $996K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.